Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of
rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with
biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with
active surveillance. T...
Age: 18 years - 66+
Gender: Male
The Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr (SAPPHIRE): A National Study
What Is SAPPHIRE?
Inflammatory bowel disease (IBD) is a condition where the body’s immune system reacts inappropriately and causes ongoing inflammation in the digestive tract. To manage this, many patients are often treated with immunosuppressants. Because...
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
The purpose of this first-in-human study is to identify a recommend dose(s) for
subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing
doses of M0324, primarily looking at safety, but also preliminary signs of efficacy,
pharmacokinet...
Age: 18 years - 66+
Gender: All
Memory Support System for Older Chinese Americans With Mild Cognitive Impairment
The Memory Support System (MSS) from the Healthy Action to Benefit Independence & Thinking® (HABIT) Program is an evidence-based, non-pharmacological intervention for mild cognitive impairment (MCI). Despite the clinical benefits and feasibility, the MSS was pri...
Age: 55 years - 66+
Gender: All
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the
risk for coronary heart disease death (CHD death), myocardial infarction, or urgent
coronary revascularization in participants at risk for a first major cardiovascular event
wit...
Age: 50 - 105 years
Gender: All
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for
Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Age: 18 years - 66+
Gender: All
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (...
Age: 18 - 69 years
Gender: All
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
The NODULE-SHOCK trial is a prospective, investigator-initiated, single-center,
randomized controlled trial designed to compare the efficacy of intravascular lithotripsy
(IVL) with or without rotational atherectomy (RA) in patients with coronary calcified
nodules (Co...
Age: 18 years - 66+
Gender: All
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
The purpose of this research study is to evaluate what type of treatment will be
beneficial for people with Crohn's disease and difficult to treat inflammation in the
small bowel. Current therapies are used to control the inflammation due to Crohn's
disease in your d...
Age: 18 - 80 years
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety,
tolerability, cellular kinetics, and biomarker changes in C-peptide over time of
GNTI-122, an investigational cell therapy manufactured from a participant's own blood
cells in adult par...
Age: 18 - 45 years
Gender: All
Human Milk Research Study
What is the purpose of the study?
The maternal RSV vaccine was licensed in 2023 for prevention of RSV-associated lower respiratory tract disease in infants up to six months of age. Maternal immunization protects infants via antibodies transferred in utero. Additional be...
Age: 18 - 50 years
Gender: Female
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approve...
Age: 18 years - 66+
Gender: All
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of
kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of
this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of
ADPKD...
Age: 18 - 55 years
Gender: All
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstr...
Age: 18 - 100 years
Gender: All
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Induction therapy approaches in recent years have evolved, now utilizing triple or
quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies,
proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients
achieve long...
Age: 70 years - 66+
Gender: All
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will
evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart
(also known as RO7790121) in participants with moderately to severely active Crohn's
disease (...
Age: 16 - 80 years
Gender: All
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive
Prenatal Test. The development of this investigational single-gene noninvasive prenatal
testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy
(SMA), Sic...
Age: 18 years - 66+
Gender: All